Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | BRAF |
Variant | T599X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | BRAF T599X indicates any BRAF missense mutation that results in replacement of the threonine (T) at amino acid 599 by a different amino acid. |
Associated Drug Resistance | |
Category Variants Paths |
BRAF mutant BRAF T599X |
Transcript | NM_004333.6 |
gDNA | chr7:g.140753338_140753340 |
cDNA | c.1795_1797 |
Protein | p.T599 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001354609.1 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_001378473.1 | chr7:g.140749326_140749328 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_001378474.1 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_004333.5 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_004333.6 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_001354609.2 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_001378468.1 | chr7:g.140753338_140753340 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
NM_001378472.1 | chr7:g.140749326_140749328 | c.1795_1797 | p.T599 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03839342 | Phase II | Binimetinib + Encorafenib | Binimetinib and Encorafenib for the Treatment of Advanced Solid Tumors With Non-V600E BRAF Mutations (BEAVER) | Active, not recruiting | CAN | 0 |